ATE469352T1 - Specific monoclonal antibody against terbinafine - Google Patents

Specific monoclonal antibody against terbinafine

Info

Publication number
ATE469352T1
ATE469352T1 AT01907523T AT01907523T ATE469352T1 AT E469352 T1 ATE469352 T1 AT E469352T1 AT 01907523 T AT01907523 T AT 01907523T AT 01907523 T AT01907523 T AT 01907523T AT E469352 T1 ATE469352 T1 AT E469352T1
Authority
AT
Austria
Prior art keywords
terbinafine
antibodies
recovering
antibody
monoclonal antibody
Prior art date
Application number
AT01907523T
Other languages
English (en)
Inventor
Birgit Dorobek
Peter Nussbaumer
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE469352T1 publication Critical patent/ATE469352T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01907523T 2000-02-14 2001-02-12 Specific monoclonal antibody against terbinafine ATE469352T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0003360.5A GB0003360D0 (en) 2000-02-14 2000-02-14 Monoclonal antibodies
PCT/EP2001/001535 WO2001059458A1 (en) 2000-02-14 2001-02-12 Specific monoclonal antibody against terbinafine

Publications (1)

Publication Number Publication Date
ATE469352T1 true ATE469352T1 (de) 2010-06-15

Family

ID=9885556

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01907523T ATE469352T1 (de) 2000-02-14 2001-02-12 Specific monoclonal antibody against terbinafine

Country Status (8)

Country Link
US (1) US7122184B2 (de)
EP (1) EP1261874B1 (de)
JP (1) JP3973424B2 (de)
AT (1) ATE469352T1 (de)
AU (1) AU3546701A (de)
DE (1) DE60142225D1 (de)
GB (1) GB0003360D0 (de)
WO (1) WO2001059458A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200821276A (en) * 2006-08-18 2008-05-16 Leo Pharma As Substituted acetylenic compounds useful for the treatment of diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2526423B1 (fr) 1982-05-07 1987-07-10 Sandoz Sa Nouvelles amines insaturees, leur preparation et leur utilisation comme medicaments
US5169773A (en) * 1984-10-04 1992-12-08 Sandoz Ltd. Monoclonal antibodies to cyclosporins
GB9111611D0 (en) 1991-05-30 1991-07-24 Sandoz Ltd Liposomes
IT1261776B (it) 1993-03-12 1996-06-03 Mendes Srl Uso di terbinafina per il trattamento terapeutico della pneumocistosi.
IL109159A (en) 1993-03-29 2003-11-23 Isk Biotech Corp Immunoassays for tetrachloroiso-phthalonitrile and its metabolites and antibodies for use therein
NZ280065A (en) * 1995-09-20 1998-04-27 Apotex Inc Preparation of n-alkyl-n-(1-naphthylmethyl)alk-2-en-4-ynylamine derivatives
IT1284076B1 (it) 1996-06-27 1998-05-08 Dox Al Italia Spa Frammenti f(ab')2 e relative immunoglobuline igg, attivi come anticorpi specifici verso farmaci e i loro metaboliti, e loro

Also Published As

Publication number Publication date
JP3973424B2 (ja) 2007-09-12
EP1261874B1 (de) 2010-05-26
DE60142225D1 (en) 2010-07-08
JP2003522537A (ja) 2003-07-29
US7122184B2 (en) 2006-10-17
GB0003360D0 (en) 2000-04-05
AU3546701A (en) 2001-08-20
WO2001059458A1 (en) 2001-08-16
US20030087323A1 (en) 2003-05-08
EP1261874A1 (de) 2002-12-04

Similar Documents

Publication Publication Date Title
ES3014740T3 (en) Treatment of cancer
NO20021992L (no) Anti-prostatastamcelleantigen(PSCA)-antistoffpreparat og fremgangsmåter for anvendelse
IL172982A0 (en) Antibodies and ca6 antigen specific cytotoxic conjugates and pharmaceutical compositions containing the same
BRPI0613382A8 (pt) anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor
MX2010005966A (es) Conjugados de anticuerpo monoclonal-molecula asociada dirigidos a la proteina tirosina-cinasa 7 (ptk7).
BRPI0613279A8 (pt) Anticorpo manoclonal isolado, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para preparar um anticorpo anti-cd19, método para inibir o crescimento de células tumorais expressando cd19, e método para depleção de celulas b num indivíduo
BR0307216A (pt) Anticorpos monoclonais humanos para antìgeno de membrana especìfica de próstata (psma)
NO20066075L (no) Antistofflegemiddelkonjugater og fremgangsmater
YU61601A (sh) Kit i postupak za radioobeležavanje antitela i postupak za odredjivanje imunoreaktivnosti radioobeleženih antitela ćelijskim vezivanjem
CR20150350A (es) Proceso para preparar conjugados de anticuerpo y maytansinoide
LU91616I2 (fr) Anticorps monoclonal hybride rat-souris(IgG2) soustoutes les formes couvertes par le brevet de base (REMOVAB - Catumaxomab)
IL186948A0 (en) Monoclonal antibodies and methods for their use in the detection of cervical disease
EP1841793A4 (de) Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
ES2214722T3 (es) Metodo de ensayo de peptidos de colageno.
UA108349C2 (uk) Гуманізоване антитіло з протипухлинною активністю
DE50011181D1 (de) Nachweis des pyruvatkinase-isoenzyms im stuhl
DE60142225D1 (en) Specific monoclonal antibody against terbinafine
DE602005015855D1 (de) Verfahren zur herstellung von immunogenen konjugaten
JPH1175839A (ja) モノクローナル抗体、細胞株及びｎ１，ｎ１２−ジアセチルスペルミンの測定法
ZA202402857B (en) Antibodies binding cldn18.2 and uses thereof
WO2026010982A2 (en) Compositions and methods for binding src
JPH06504424A (ja) モノクローナル抗ＩｇＭ抗体、その生産と使用、およびそれらを生産するためのハイブリドーマ
Carruthers et al. Detection of liver-bound metabolites of azocarcinogens by the use of anti-hapten antibodies
RU2001130143A (ru) Способ количественной оценки трансформирующего фактора роста бета 1 и - с его помощью - способ обнаружения рака
SI9600206B (sl) Monoklonska protitelesa proti topnima TNF-alfa receptorjema p55 in p75 ter TNF-alfa in njegovim analogom

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties